Clinical Trial Update: Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia [Phase 3]

View source ↗

Summary

An open-label Phase 3 pilot study evaluating memantine's effects on FDG-PET imaging in Frontotemporal dementia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: Tiffany Chow, MD | Conditions: Frontotemporal Dementia | Phase 3 | Status: COMPLETED